What is BaseCase? Video What is BaseCase? Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams…CertaraJuly 20, 2021
Strategic Planning and technology to support a rolling BLA submission under tight timelines Case Study Strategic Planning and technology to support a rolling BLA submission under tight timelines A Tier 3 Sponsor called upon Certara to support its rolling BLA submission, the second…CertaraJuly 19, 2021
Open-Source Modeling Tools: Fueling the Fire vs. Extinguishing the Debate On-Demand Webinar Open-Source Modeling Tools: Fueling the Fire vs. Extinguishing the Debate The paper “Opening a Debate on Open-Source Modelling Tools: Pouring Fuel on Fire vs. Extinguishing…CertaraJuly 15, 2021
Determining Exposures when Transitioning Between Combination Treatments in Cystic Fibrosis: Trikafta Case Study Determining Exposures when Transitioning Between Combination Treatments in Cystic Fibrosis: Trikafta Many cystic fibrosis (CF) patients take several medications at one time to manage symptoms and…CertaraJuly 14, 2021
Voxelotor for Treating Sickle Cell Disease: Leveraging Dose Prediction Model for DDI Prediction Without Any Clinical Studies Case Study Voxelotor for Treating Sickle Cell Disease: Leveraging Dose Prediction Model for DDI Prediction Without Any Clinical Studies In November 2019, the US FDA granted accelerated approval for Oxbryta™ (voxelotor) tablets for the…CertaraJuly 14, 2021
Key Considerations to Ensure Maximal Probability of Antibody Drug Conjugate Development Success Blog Key Considerations to Ensure Maximal Probability of Antibody Drug Conjugate Development Success Antibody drug conjugates (ADC) are a unique way to obliterate tumor cells and represent an…CertaraJuly 8, 2021
Meet a Certara regulatory operations specialist Video Meet a Certara regulatory operations specialist Meet Rachel Bombara, Sr. Regulatory Operations Specialist at Certara. In this brief video Rachel shares…CertaraJuly 2, 2021
Maximizing Oligonucleotide Therapeutic Development: Pre-clinical and Translational Considerations Blog Maximizing Oligonucleotide Therapeutic Development: Pre-clinical and Translational Considerations This is the second of three blog posts discussing best practices for developing oligonucleotide therapeutics.…CertaraJune 25, 2021
Complex patient profile and narrative template needs Case Study Complex patient profile and narrative template needs A global pharmaceutical company came to Certara to generate both patient profile (PPL) and narrative…CertaraJune 24, 2021
Fundamentals of regulatory writing: the document development process Press Coverage Fundamentals of regulatory writing: the document development process Regulatory writers lead the development of high-quality regulatory documents by working incollaboration with colleagues across…CertaraJune 22, 2021